Biosimilar Cancer Drugs in India — What They Are and How They Differ

A biosimilar is a biological medicine — made from living cells — that has been shown to be highly similar to an already-approved original, called the reference product. It is not chemically identical, because biological medicines are too large and complex for that. What it must demonstrate is that any differences between it and the original do not meaningfully affect safety or how the medicine works. CDSCO reviews and approves that evidence before the biosimilar can be used in India.

No. A generic drug is chemically identical to its original — the same molecule, made the same way. A biosimilar is made from living cells and is highly similar but not identical, because no two batches of a biological medicine are ever perfectly identical, even the original. Because of this complexity, biosimilars require more extensive regulatory review than generics, and cannot be substituted as automatically as a generic would be.

Yes. CDSCO has a defined approval pathway for biosimilars, first formalised in 2012. A biosimilar must submit clinical evidence of similarity to its reference product and receive CDSCO approval before it can be marketed or prescribed. If a biosimilar appears on your prescription or is administered at a registered clinic in India, it has gone through that process.

CDSCO approval requires evidence that there are no clinically meaningful differences in safety from the original. Biosimilars do not receive approval on the assumption that they are safe — they are required to prove it. Any biological medicine, whether original or biosimilar, carries the possibility of infusion reactions and other effects that your clinical team will monitor for. The monitoring approach is the same for both.

The company making a biosimilar does not carry the research and development costs of discovering the original medicine. It still has to invest in manufacturing and the regulatory studies required for approval, but those costs are lower. That difference is passed on, at least in part, as a lower price. For some cancer biologics that carry very high original list prices, biosimilars can make treatment meaningfully more accessible.

Your oncologist should explain any change to the medicine you are receiving. Switching — from a reference product to a biosimilar, or from one biosimilar to another — is a clinical decision that should involve you. If a different brand appears on your prescription or is dispensed without explanation, ask directly. It is reasonable to understand exactly what you are being given, and your team should be able to explain it.